Targeting the immune system: a new antibody may free Graves' patients from daily drugs

NCT ID NCT07722546

Not yet recruiting Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether felzartamab, an antibody that targets immune cells producing harmful antibodies, can restore normal thyroid function in people with Graves' disease. Participants will receive either felzartamab or a placebo alongside their usual anti-thyroid drugs, with the goal of eventually stopping those drugs. The study will measure how many people achieve normal thyroid levels without medication after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antibody drug called felzartamab
What this could lead to: If successful, felzartamab could offer a new treatment option for Graves' disease, potentially allowing patients to stop taking daily anti-thyroid drugs.
What could go wrong: This is an early phase 2 trial with only 60 participants. The drug may not work better than placebo, and side effects from targeting immune cells are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES' DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease hyperthyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES' DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.